{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T23:07:34Z","timestamp":1778108854819,"version":"3.51.4"},"reference-count":36,"publisher":"Impact Journals, LLC","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,5,20]]},"DOI":"10.18632\/oncotarget.3665","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T06:34:31Z","timestamp":1442298871000},"page":"12128-12140","source":"Crossref","is-referenced-by-count":31,"title":["Discovery of a small molecule targeting SET-PP2A interaction to overcome BCR-ABLT315I mutation of chronic myeloid leukemia"],"prefix":"10.18632","volume":"6","author":[{"given":"Shuzhen","family":"Wang","sequence":"first","affiliation":[{"name":"State Key Laboratory of Natural Medicines and Laboratory of Chemical Biology, China Pharmaceutical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiquan","family":"Xie","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines and Laboratory of Chemical Biology, China Pharmaceutical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duowei","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines and Institute of Pharmaceutical Science, China Pharmaceutical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Peng","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines and Laboratory of Chemical Biology, China Pharmaceutical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zheng","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines and Institute of Pharmaceutical Science, China Pharmaceutical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines and Laboratory of Chemical Biology, China Pharmaceutical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Dai","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines and Laboratory of Chemical Biology, China Pharmaceutical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines and Laboratory of Chemical Biology, China Pharmaceutical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zongqiang","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines and Laboratory of Chemical Biology, China Pharmaceutical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines and Institute of Pharmaceutical Science, China Pharmaceutical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijun","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines and Laboratory of Chemical Biology, China Pharmaceutical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2015,3,26]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrd2324","article-title":"Flying under the radar: the new wave of BCR-ABL inhibitors","volume":"6","author":"Cortes","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"2","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1158\/1078-0432.CCR-08-0117","article-title":"Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia","volume":"14","author":"Cortes","year":"2008","journal-title":"Clin Cancer Res"},{"key":"3","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1053\/j.seminhematol.2010.06.004","article-title":"Third-generation tyrosine kinase inhibitors and beyond","volume":"47","author":"Cortes","year":"2010","journal-title":"Semin Hematol"},{"key":"4","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"Deininger","year":"2007","journal-title":"Blood"},{"key":"5","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1158\/1078-0432.CCR-09-3314","article-title":"Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia","volume":"17","author":"Druker","year":"2011","journal-title":"Clin Cancer Res"},{"key":"6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nbt0114-9a","article-title":"FDA halts then allows sales of Ariad's leukemia medication","volume":"32","author":"Senior","year":"2014","journal-title":"Nat Biotechnol"},{"key":"7","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase","volume":"289","author":"Kuriyan","year":"2000","journal-title":"Science"},{"key":"8","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1021\/jm8010542","article-title":"Kinase domain mutations in cancer: implications for small molecule drug design strategies","volume":"52","author":"Mansour","year":"2009","journal-title":"J Med Chem"},{"key":"9","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1158\/1078-0432.CCR-04-2458","article-title":"EphB2 expression across 138 human tumor types in a tissue microarray: high levels of expression in gastrointestinal cancers","volume":"11","author":"Tornillo","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nbt1328","article-title":"Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors","volume":"25","author":"Sweetman","year":"2007","journal-title":"Nat Biotechnol"},{"key":"11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ab.2006.02.008","article-title":"A versatile method of identifying specific binding proteins on affinity resins","volume":"352","author":"Tanaka","year":"2006","journal-title":"Anal Biochem"},{"key":"12","doi-asserted-by":"crossref","first-page":"e52536","DOI":"10.1371\/journal.pone.0052536","article-title":"The apoptotic effects of toosendanin are partially mediated by activation of deoxycytidine kinase in HL-60 cells","volume":"7","author":"Chen","year":"2012","journal-title":"PloS one"},{"key":"13","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/sj.leu.2402257","article-title":"The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy","volume":"15","author":"Neckers","year":"2001","journal-title":"Leukemia"},{"key":"14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"Wilson","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"15","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0959-4388(97)80066-9","article-title":"Sequential roles of agrin, MuSK and rapsyn during neuromuscular junction formation","volume":"7","author":"Yancopoulos","year":"1997","journal-title":"Curr Opin Neurobiol"},{"key":"16","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1083\/jcb.108.5.1833","article-title":"The mammalian 43-kD acetylcholine receptor-associated protein (RAPsyn) is expressed in some nonmuscle cells","volume":"108","author":"Merlie","year":"1989","journal-title":"J Cell Biol"},{"key":"17","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/ncomms1093","article-title":"Protein-binding assays in biological liquids using microscale thermophoresis","volume":"1","author":"Duhr","year":"2010","journal-title":"Nat Commun"},{"key":"18","doi-asserted-by":"crossref","first-page":"11059","DOI":"10.1074\/jbc.271.19.11059","article-title":"The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A","volume":"271","author":"Damuni","year":"1996","journal-title":"J Biol Chem"},{"key":"19","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1038\/onc.2010.622","article-title":"Targeting SET\/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy","volume":"30","author":"Vitek","year":"2011","journal-title":"Oncogene"},{"key":"20","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","article-title":"BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships","volume":"121","author":"Eiring","year":"2013","journal-title":"Blood"},{"key":"21","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Jabbour","year":"2014","journal-title":"Cancer Cell"},{"key":"22","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1039\/b702942j","article-title":"Identification of the cellular targets of bioactive small organic molecules using affinity reagents","volume":"37","author":"Hergenrother","year":"2008","journal-title":"Chem Soc Rev"},{"key":"23","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","article-title":"The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein","volume":"8","author":"Valtieri","year":"2005","journal-title":"Cancer cell"},{"key":"24","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/sj.bjc.6603317","article-title":"ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia","volume":"95","author":"Neviani","year":"2006","journal-title":"Br J Cancer"},{"key":"25","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1172\/JCI31095","article-title":"FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia","volume":"117","author":"Cortes","year":"2007","journal-title":"J Clin Invest"},{"key":"26","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1182\/blood-2011-04-351072","article-title":"SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target","volume":"118","author":"Diehl","year":"2011","journal-title":"Blood"},{"key":"27","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/leu.2010.294","article-title":"PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect","volume":"25","author":"Odero","year":"2011","journal-title":"Leukemia"},{"key":"28","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1172\/JCI68951","article-title":"PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells","volume":"123","author":"Mao","year":"2013","journal-title":"J Clin Invest"},{"key":"29","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1158\/1078-0432.CCR-13-2575","article-title":"Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia","volume":"20","author":"Druker","year":"2014","journal-title":"Clin Cancer Res"},{"key":"30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2006-10-053884","article-title":"FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia\/lymphoma","volume":"111","author":"Byrd","year":"2008","journal-title":"Blood"},{"key":"31","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/jcb.24003","article-title":"Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation","volume":"113","author":"Huang","year":"2012","journal-title":"J Cell Biochem"},{"key":"32","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/emmm.201201283","article-title":"Sphingosine analogue drug FTY720 targets I2PP2A\/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis","volume":"5","author":"Garrett-Mayer","year":"2013","journal-title":"EMBO Mol Med"},{"key":"33","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1096\/fj.08-120550","article-title":"Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling","volume":"23","author":"Ogretmen","year":"2009","journal-title":"FASEB J"},{"key":"34","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.bmcl.2009.11.032","article-title":"The identification of structurally novel, selective, orally bioavailable positive modulators of mGluR2","volume":"20","author":"Osborne","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"35","doi-asserted-by":"crossref","first-page":"e47476","DOI":"10.1371\/journal.pone.0047476","article-title":"Comparative proteomic profiling of human bile reveals SSP411 as a novel biomarker of cholangiocarcinoma","volume":"7","author":"Wang","year":"2012","journal-title":"PloS one"},{"key":"36","first-page":"4623","article-title":"Taxol induction of p21WAF1 and p53 requires c-raf-1","volume":"55","author":"Neckers","year":"1995","journal-title":"Cancer Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.3665","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T11:25:02Z","timestamp":1589369102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.3665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,26]]},"references-count":36,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2015,5,20]]}},"alternative-id":["3665","25900240"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.3665","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,26]]}}}